; Tekmira Pharmaceuticals Corp. (TKM) - Financial and Strategic SWOT Analysis Review
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Tekmira Pharmaceuticals Corp. (TKM) - Financial and Strategic SWOT Analysis Review

VIEWS: 22 PAGES: 43

Tekmira Pharmaceuticals Corp. (Tekmira) is a biopharmaceutical company focused on the development and commercialization of proprietary drugs and drug delivery systems indicated for the treatment of cancer and other diseases. The company's product pipeline consists of TKM-PLK1 and WEE1/CSN5, administered to treat cancer, TKM-Ebola, developed against hemorrhagic fever viruses, TKM-ApoB, evaluated to treat high levels of low-density lipoprotein cholesterol and TKM-ALDH2, designed for the treatment of alcohol dependence. Its LNP delivery technology allows siRNA to be enclosed in a particle made of lipids that can be administered into a vein to target infected areas such as liver or cancerous tumors. The technology is used in the development of partner products such as ALN-VSP, ALN-TTR01, ALN-TTR02, ALN-PCS and others. The company entered various partnership and collaboration agreements with leading companies in the RNAi field, such as Bristol-Myers Squibb, Alnylam, Halo-Bio, Talon Therapeutics, Inc., Aradigm and Merck. It reports its business through a single segment, namely, the research and development of RNA interference therapeutics. The company along with its subsidiaries, namely, Protiva Biotherapeutics Inc. and Protiva Biotherapeutics (USA) Inc. operates in the US and Canada. Tekmira is headquartered in British Columbia, Canada. The company's seeks to research, develop, manufacture and commercialize its product portfolio through strategic collaborations with industry leaders and academic institutes and support the development of partner candidates that use its lipid nanoparticle (LNP) delivery technology.

More Info
  • pg 1
									          Tekmira Pharmaceuticals Corp. (TKM) - Financial and Strategic SWOT
                                  Analysis Review
        Reference Code: GDPH4335FSA                                                                                           Publication Date: AUG 2012

          100 - 8900 Glenlyon Parkway                        Phone              +1 604 4193200                  Revenue          16.65 (million CAD)
          BURNABY, BC                                        Fax                +1 604 4193201                  Net Profit       -9.94 (million CAD)
          V5J 5J8                                            Website            www.tekmirapharm.com            Employees        85
                                                                                TKM [Toronto         Stock                       Pharmaceuticals           &
          Canada                                             Exchange                                           Industry
                                                                                Exchange]                                        Healthcare

       Company Overview
       Tekmira Pharmaceuticals Corp. (Tekmira) is a biopharmaceutical company focused on the development and commercialization of
       proprietary drugs and drug delivery systems indicated for the treatment of cancer and other diseases. The company's product
       pipeline consists of TKM-PLK1 and WEE1/CSN5, administered to treat cancer, TKM-Ebola, developed against hemorrhagic fever
       viruses, TKM-ApoB, evaluated to treat high levels of low-density lipoprotein cholesterol and TKM-ALDH2, designed for the
       treatment of alcohol dependence.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Tekmira Pharmaceuticals Corp., SWOT Analysis
         Mark J. Murray, Ph.D.               Chief Executive Officer                  Strengths                              Weaknesses
         Daniel Kisner, M.D.                 Chairman
                                                                                      Proprietary Technology                 Decline in Liquidity Reserves
         Michael J. Abrams, Ph.D.            Director
                                                                                      Intellectual Property Portfolio        Legal Proceedings
         Donald Jewell                       Director
         Ken Galbraith                       Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Therapeutic Product Pipeline           Uncertain R&D Outcomes
       Share Data
                                                                                      Changing Demographics                  Stringent Government
         Tekmira Pharmaceuticals Corp.
                                                                                                                             Regulations
        Share Price (CAD) as on 16-Aug-                                  3.78
        2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (CAD)                                                       -0.88        GlobalData
        Market Cap (million CAD)                                           52
        Enterprise Value (million CAD)                                     44
        Shares Outstanding (million)                                       14
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Aug 06, 2012         Tekmira Provides Update On Collaboration
                                                                                                           With US Government's TMT Program
                                                                                      May 15, 2012         Tekmira Pharma Reports               Revenue        Of
                                                                                                           CAD3.6m In Q1 2012
                                                                                      Mar 27, 2012         Tekmira Pharma          Reports      Revenue        Of
                                                                                                           CAD16.6m In 2011
                                                                                      Mar 06, 2012         Tekmira Files Motion To Dismiss In Patent
                                                                                                           Infringement Suit
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Tekmira Pharmaceuticals Corp. (TKM) - Financial and Strategic                                                                   Reference Code: GDPH4335FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                      Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Tekmira Pharmaceuticals Corp. - Key Facts ...................................................................................................................................... 5
       Tekmira Pharmaceuticals Corp. - Key Employees ............................................................................................................................. 6
       Tekmira Pharmaceuticals Corp. - Key Employee Biographies ........................................................................................................... 7
       Tekmira Pharmaceuticals Corp. - Major Products and Services ........................................................................................................ 8
       Tekmira Pharmaceuticals Corp. - Pharmaceutical Pipeline Products Data ........................................................................................ 9
          Tekmira Pharmaceuticals Corp., Pipeline Products by Therapy Area ............................................................................................ 9
          Tekmira Pharmaceuticals Corp., Pipeline Products by Development Phase ................................................................................ 10
       Tekmira Pharmaceuticals Corp. - History ......................................................................................................................................... 12
       Tekmira Pharmaceuticals Corp. - Company Statement ................................................................................................................... 14
       Tekmira Pharmaceuticals Corp. - Locations And Subsidiaries ......................................................................................................... 19
          Head Office ................................................................................................................................................................................... 19
          Other Locations & Subsidiaries ..................................................................................................................................................... 19
       Section 2 – Company Analysis ......................................................................................................................................................... 20
       Tekmira Pharmaceuticals Corp. - Business Description................................................................................................................... 20
       Tekmira Pharmaceuticals Corp. - SWOT Analysis ........................................................................................................................... 21
          SWOT Analysis - Overview........................................................................................................................................................... 21
          Tekmira Pharmaceuticals Corp. - Strengths ................................................................................................................................. 21
             Strength - Proprietary Technology ............................................................................................................................................ 21
             Strength - Intellectual Property Portfolio .................................................................................................................................... 21
             Strength - Strategic Agreements ............................................................................................................................................... 21
          Tekmira Pharmaceuticals Corp. - Weaknesses ............................................................................................................................ 22
             Weakness - Decline in Liquidity Reserves ................................................................................................................................ 22
             Weakness - Legal Proceedings ................................................................................................................................................. 22
             Weakness - History of Operating Loss ...................................................................................................................................... 22
          Tekmira Pharmaceuticals Corp. - Opportunities ........................................................................................................................... 22
             Opportunity - Therapeutic Product Pipeline............................................................................................................................... 22
             Opportunity - Changing Demographics ..................................................................................................................................... 23
             Opportunity - Focus on Key Therapeutic Areas ........................................................................................................................ 23
          Tekmira Pharmaceuticals Corp. - Threats .................................................................................................................................... 23
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 23
             Threat - Stringent Government Regulations .............................................................................................................................. 23
             Threat - Intense Competition ..................................................................................................................................................... 24
       Tekmira Pharmaceuticals Corp. - Key Competitors.......................................................................................................................... 25
       Section 3 – Company Financial Ratios ............................................................................................................................................. 26
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 26
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 26
       Performance Chart ........................................................................................................................................................................... 28
       Financial Performance...................................................................................................................................................................... 28
       Financial Ratios - Interim Ratios....................................................................................................................................................... 29
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 30
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 31


Tekmira Pharmaceuticals Corp. (TKM) - Financial and Strategic                                                                                                    Reference Code: GDPH4335FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Tekmira Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 .......................................... 31
          Tekmira Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 ......................................... 32
       Tekmira Pharmaceuticals Corp., Recent Deals Summary................................................................................................................ 33
       Section 5 – Company’s Recent Developments ................................................................................................................................ 34
          Tekmira Pharmaceuticals Corp., Recent Developments............................................................................................................... 34
             Aug 06, 2012: Tekmira Provides Update On Collaboration With US Government's TMT Program........................................... 34
             May 15, 2012: Tekmira Pharma Reports Revenue Of CAD3.6m In Q1 2012 ........................................................................... 34
             Mar 27, 2012: Tekmira Pharma Reports Revenue Of CAD16.6m In 2011 ................................................................................ 36
             Mar 06, 2012: Tekmira Files Motion To Dismiss In Patent Infringement Suit ............................................................................ 36
             Mar 01, 2012: Tekmira Expands Product Pipeline With RNAi Therapeutic For Treatment Of Alcohol Dependence................. 36
             Feb 09, 2012: Tekmira Announces USPTO Issuance Of Key Patents Broadly Covering LNP Formulations And Mitigation Of
             Immune Stimulation................................................................................................................................................................... 37
             Jan 17, 2012: Alnylam Files Patent Infringement Suit Against Tekmira .................................................................................... 37
             Jan 17, 2012: Tekmira Provides Periodic Update On Litigation Against Alnylam........................
								
To top